Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cIPV + bOPV
- Development stage
- Unknown
- Lead developer
- Panacea Biotec
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Oral
01
Overview
cIPV + bOPV is a sequential immunization strategy that combines conventional inactivated poliovirus vaccine (cIPV) with bivalent oral polio vaccine (bOPV). This approach is used as part of the global polio eradication initiative, particularly after the switch from trivalent OPV (tOPV). The strategy aims to provide immunity against all poliovirus types while reducing the risk of vaccine-derived poliovirus infections. The immunization schedule typically involves administering cIPV first, followed by bOPV doses.
- Brand names
- IpolOrimune
- Other names
- conventional inactivated poliovirus vaccine + bivalent oral polio vaccine
Beyond the preview
Go deeper on cIPV + bOPV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cIPV + bOPV.